[Top] [All Lists]

[e-lek] cost of developing

Уважаемые коллеги,
в Бр Мед Ж опубликована статья, посвященная фармацевтическим инновациям

Pharmaceutical research and development: what do we get for all that money?
BMJ 2012; 345 doi: 10.1136/bmj.e4348 (Published 7 August 2012)
     Donald W Light, professor 1,
     Joel R Lexchin, professor2
В ней много интересного, но в отношение цены разработки вот абзац:
How much does research and development cost?

Although the pharmaceutical industry emphasises how much money it 
devotes to discovering new drugs, little of that money actually goes 
into basic research. Data from companies, the United States National 
Science Foundation, and government reports indicate that companies have 
been spending only 1.3% of revenues on basic research to discover new 
molecules, net of taxpayer subsidies.23 More than four fifths of all 
funds for basic research to discover new drugs and vaccines come from 
public sources.24 Moreover, despite the industry’s frequent claims that 
the cost of new drug discovery is now $1.3bn (£834m; €1bn),25 this 
figure, which comes from the industry supported Tufts Center,26 has been 
heavily criticised. Half that total comes from estimating how much 
profit would have been made if the money had been invested in an index 
fund of pharmaceutical companies that increased in value 11% a year, 
compounded over 15 years.26 While used by finance committees to estimate 
whether a new venture is worth investing in, these presumed profits (far 
greater than the rise in the value of pharmaceutical stocks) should not 
be counted as research and development costs on which profits are to be 
made. Half of the remaining $0.65bn is paid by taxpayers through company 
deductions and credits, bringing the estimate down to one quarter of 
$1.3bn or $0.33bn.27 The Tufts study authors report that their estimate 
was done on the most costly fifth of new drugs (those developed 
in-house), which the authors reported were 3.44 times more costly than 
the average, reducing the estimate to $90m. The median costs were a 
third less than the average, or $60m. Deconstructing other inflators 
would lower the estimate of costs even further.

Vasiliy V. Vlassov, MD
President, Society for Evidence Based Medicine
e-mail: vlassov[a t]cochrane.ru
snail mail: P.O.Box 13 Moscow 109451 Russia
FAX: USA +1-215-2611492; Russia +7(495)6549353

<Prev in Thread] Current Thread [Next in Thread>
  • [e-lek] cost of developing, v vlassov <=